-+ 0.00%
-+ 0.00%
-+ 0.00%

Keros Therapeutics Board Authorizes Additional $5 Million Share Repurchase Program

PUBT·11/16/2026 21:11:35
Listen to the news
Keros Therapeutics Board Authorizes Additional $5 Million Share Repurchase Program
  • Keros Therapeutics' board expanded its share repurchase authorization today with a new $5 million program for common stock.
  • The program follows a $20 million elritercept milestone payment from Takeda, triggered by first-patient dosing in the ELRiSE MF trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-26-000072), on November 16, 2026, and is solely responsible for the information contained therein.